Eintrag weiter verarbeiten
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Sig...
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 30, 2012, 25, S. 3109-3118 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Mendler, Jason H. Maharry, Kati Radmacher, Michael D. Mrózek, Krzysztof Becker, Heiko Metzeler, Klaus H. Schwind, Sebastian Whitman, Susan P. Khalife, Jihane Kohlschmidt, Jessica Nicolet, Deedra Powell, Bayard L. Carter, Thomas H. Wetzler, Meir Moore, Joseph O. Kolitz, Jonathan E. Baer, Maria R. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. Mendler, Jason H. Maharry, Kati Radmacher, Michael D. Mrózek, Krzysztof Becker, Heiko Metzeler, Klaus H. Schwind, Sebastian Whitman, Susan P. Khalife, Jihane Kohlschmidt, Jessica Nicolet, Deedra Powell, Bayard L. Carter, Thomas H. Wetzler, Meir Moore, Joseph O. Kolitz, Jonathan E. Baer, Maria R. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. |
|---|---|
| author |
Mendler, Jason H. Maharry, Kati Radmacher, Michael D. Mrózek, Krzysztof Becker, Heiko Metzeler, Klaus H. Schwind, Sebastian Whitman, Susan P. Khalife, Jihane Kohlschmidt, Jessica Nicolet, Deedra Powell, Bayard L. Carter, Thomas H. Wetzler, Meir Moore, Joseph O. Kolitz, Jonathan E. Baer, Maria R. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. |
| spellingShingle |
Mendler, Jason H. Maharry, Kati Radmacher, Michael D. Mrózek, Krzysztof Becker, Heiko Metzeler, Klaus H. Schwind, Sebastian Whitman, Susan P. Khalife, Jihane Kohlschmidt, Jessica Nicolet, Deedra Powell, Bayard L. Carter, Thomas H. Wetzler, Meir Moore, Joseph O. Kolitz, Jonathan E. Baer, Maria R. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. Journal of Clinical Oncology RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures Cancer Research Oncology |
| author_sort |
mendler, jason h. |
| spelling |
Mendler, Jason H. Maharry, Kati Radmacher, Michael D. Mrózek, Krzysztof Becker, Heiko Metzeler, Klaus H. Schwind, Sebastian Whitman, Susan P. Khalife, Jihane Kohlschmidt, Jessica Nicolet, Deedra Powell, Bayard L. Carter, Thomas H. Wetzler, Meir Moore, Joseph O. Kolitz, Jonathan E. Baer, Maria R. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2011.40.6652 <jats:sec><jats:title>Purpose</jats:title><jats:p> To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation–associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches. </jats:p></jats:sec> <i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2011.40.6652 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS40MC42NjUy |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS40MC42NjUy |
| institution |
DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2012 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
mendler2012runx1mutationsareassociatedwithpooroutcomeinyoungerandolderpatientswithcytogeneticallynormalacutemyeloidleukemiaandwithdistinctgeneandmicrornaexpressionsignatures |
| publishDateSort |
2012 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_unstemmed |
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_full |
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_fullStr |
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_full_unstemmed |
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_short |
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_sort |
<i>runx1</i> mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microrna expression signatures |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2011.40.6652 |
| publishDate |
2012 |
| physical |
3109-3118 |
| description |
<jats:sec><jats:title>Purpose</jats:title><jats:p> To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation–associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches. </jats:p></jats:sec> |
| container_issue |
25 |
| container_start_page |
3109 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348132524163072 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:06:15.654Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=RUNX1+Mutations+Are+Associated+With+Poor+Outcome+in+Younger+and+Older+Patients+With+Cytogenetically+Normal+Acute+Myeloid+Leukemia+and+With+Distinct+Gene+and+MicroRNA+Expression+Signatures&rft.date=2012-09-01&genre=article&issn=1527-7755&volume=30&issue=25&spage=3109&epage=3118&pages=3109-3118&jtitle=Journal+of+Clinical+Oncology&atitle=%3Ci%3ERUNX1%3C%2Fi%3E+Mutations+Are+Associated+With+Poor+Outcome+in+Younger+and+Older+Patients+With+Cytogenetically+Normal+Acute+Myeloid+Leukemia+and+With+Distinct+Gene+and+MicroRNA+Expression+Signatures&aulast=Bloomfield&aufirst=Clara+D.&rft_id=info%3Adoi%2F10.1200%2Fjco.2011.40.6652&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348132524163072 |
| author | Mendler, Jason H., Maharry, Kati, Radmacher, Michael D., Mrózek, Krzysztof, Becker, Heiko, Metzeler, Klaus H., Schwind, Sebastian, Whitman, Susan P., Khalife, Jihane, Kohlschmidt, Jessica, Nicolet, Deedra, Powell, Bayard L., Carter, Thomas H., Wetzler, Meir, Moore, Joseph O., Kolitz, Jonathan E., Baer, Maria R., Carroll, Andrew J., Larson, Richard A., Caligiuri, Michael A., Marcucci, Guido, Bloomfield, Clara D. |
| author_facet | Mendler, Jason H., Maharry, Kati, Radmacher, Michael D., Mrózek, Krzysztof, Becker, Heiko, Metzeler, Klaus H., Schwind, Sebastian, Whitman, Susan P., Khalife, Jihane, Kohlschmidt, Jessica, Nicolet, Deedra, Powell, Bayard L., Carter, Thomas H., Wetzler, Meir, Moore, Joseph O., Kolitz, Jonathan E., Baer, Maria R., Carroll, Andrew J., Larson, Richard A., Caligiuri, Michael A., Marcucci, Guido, Bloomfield, Clara D., Mendler, Jason H., Maharry, Kati, Radmacher, Michael D., Mrózek, Krzysztof, Becker, Heiko, Metzeler, Klaus H., Schwind, Sebastian, Whitman, Susan P., Khalife, Jihane, Kohlschmidt, Jessica, Nicolet, Deedra, Powell, Bayard L., Carter, Thomas H., Wetzler, Meir, Moore, Joseph O., Kolitz, Jonathan E., Baer, Maria R., Carroll, Andrew J., Larson, Richard A., Caligiuri, Michael A., Marcucci, Guido, Bloomfield, Clara D. |
| author_sort | mendler, jason h. |
| container_issue | 25 |
| container_start_page | 3109 |
| container_title | Journal of Clinical Oncology |
| container_volume | 30 |
| description | <jats:sec><jats:title>Purpose</jats:title><jats:p> To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation–associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches. </jats:p></jats:sec> |
| doi_str_mv | 10.1200/jco.2011.40.6652 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS40MC42NjUy |
| imprint | American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2012 |
| institution | DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T18:06:15.654Z |
| match_str | mendler2012runx1mutationsareassociatedwithpooroutcomeinyoungerandolderpatientswithcytogeneticallynormalacutemyeloidleukemiaandwithdistinctgeneandmicrornaexpressionsignatures |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 3109-3118 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Mendler, Jason H. Maharry, Kati Radmacher, Michael D. Mrózek, Krzysztof Becker, Heiko Metzeler, Klaus H. Schwind, Sebastian Whitman, Susan P. Khalife, Jihane Kohlschmidt, Jessica Nicolet, Deedra Powell, Bayard L. Carter, Thomas H. Wetzler, Meir Moore, Joseph O. Kolitz, Jonathan E. Baer, Maria R. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2011.40.6652 <jats:sec><jats:title>Purpose</jats:title><jats:p> To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated with ASXL1 mutations (P < .001) and inversely associated with NPM1 (P < .001) and CEBPA (P = .06) mutations. RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older) and shorter disease-free survival (P = .058 in younger; P < .001 in older), overall survival (P = .003 in younger; P < .001 in older), and event-free survival (P < .001 for younger and older) than RUNX1 wild-type patients. Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation–associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups. RUNX1-mutated blasts have molecular features of primitive hematopoietic and lymphoid progenitors, potentially leading to novel therapeutic approaches. </jats:p></jats:sec> <i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures Journal of Clinical Oncology |
| spellingShingle | Mendler, Jason H., Maharry, Kati, Radmacher, Michael D., Mrózek, Krzysztof, Becker, Heiko, Metzeler, Klaus H., Schwind, Sebastian, Whitman, Susan P., Khalife, Jihane, Kohlschmidt, Jessica, Nicolet, Deedra, Powell, Bayard L., Carter, Thomas H., Wetzler, Meir, Moore, Joseph O., Kolitz, Jonathan E., Baer, Maria R., Carroll, Andrew J., Larson, Richard A., Caligiuri, Michael A., Marcucci, Guido, Bloomfield, Clara D., Journal of Clinical Oncology, RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures, Cancer Research, Oncology |
| title | RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_full | RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_fullStr | RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_full_unstemmed | RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_short | RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| title_sort | <i>runx1</i> mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microrna expression signatures |
| title_unstemmed | RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2011.40.6652 |